Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
11. August 2020 04:06 ET
|
Kymab Group Ltd
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity...
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON
24. Juni 2020 05:29 ET
|
Kymab Group Ltd
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company...
Kymab announces that the US Patent Trial and Appeal Board rejects a fifth request by Regeneron for invalidation of Kymab’s US patents
03. Juni 2020 07:00 ET
|
Kymab Group Ltd
Kymab announces that the US Patent Trial and Appeal Board rejects a fifthrequest by Regeneron for invalidation of Kymab’s US patents USPTO upholds a fifth Kymab patent covering Human Antibodies and...
Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron
14. April 2020 07:00 ET
|
Kymab Group Ltd
Kymab announces that the US Patent Trial and Appeal Board rejects requests for invalidation filed by Regeneron USPTO upholds 4 Kymab patents covering Human Antibodies and Platforms Cambridge, UK:...
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition
06. Dezember 2019 07:00 ET
|
Kymab Group Ltd
Kymab Presents Updates at the American Society of Hematology (ASH) 61st Annual Meeting and Exposition Cambridge, UK; December 6, 2019: Kymab, a clinical-stage biopharmaceutical company developing...
Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting
08. November 2019 07:00 ET
|
Kymab Group Ltd
Kymab Presents Update on Lead Immunocytokine Program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting KY1043, a bifunctional, PD-L1-based, IL-2Ra (CD25)-directed immunocytokine...
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting
27. September 2019 02:00 ET
|
Kymab Group Ltd
Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting KY1044 increases the ratio of intratumoral cytotoxic-to-regulatory T cells and induces tumor...
Kymab Appoints Catherine Moukheibir as Non-Executive Director
16. Juli 2019 07:00 ET
|
Kymab Group Ltd
Kymab Appoints Catherine Moukheibir as Non-Executive Director Cambridge, UK; July 16, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, announces the...
Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
24. Juni 2019 07:00 ET
|
Kymab Group Ltd
Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies LifeArc will make a US$30 million equity investment in KymabLifeArc to gain access to...
Kymab Announces Presentations at the 24th EHA Annual Congress
13. Juni 2019 09:00 ET
|
Kymab Group Ltd
Kymab Announces Presentations at the 24th EHA Annual Congress Two Company-sponsored oral and poster abstracts to be presented on KY1049 and IntelliSelect® Bispecifics platform Cambridge, UK; June...